Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | FPR2 | P25090 | 1/20 | 0.43 |
| ▸ | KDM5A | P29375 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 2/20 | 0.37 |
| ▸ | HTR2A | P28223 | 2/20 | 0.37 |
| ▸ | DRD3 | P35462 | 2/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9891797 | 0.86 | KDM4E (0.51) | KDM4EFPR2KDM5AALDH1A1P2RX4 | |
| SCHEMBL10257034 | 0.83 | — | — | |
| SCHEMBL13321380 | 0.83 | KDM4E (0.49) | KDM4EFPR2ALDH1A1P2RX4EPHX2 | |
| SCHEMBL18705061 | 0.83 | ALDH1A1 (0.51) | KDM4EKDM5AALDH1A1EPHX2EPHX1 | |
| SCHEMBL21835882 | 0.83 | KDM4E (0.49) | KDM4EFPR2ALDH1A1P2RX4EPHX2 | |
| SCHEMBL24308498 | 0.80 | KDM4E (0.54) | KDM4EALDH1A1EPHX2EPHX1DRD2 | |
| SCHEMBL10098777 | 0.80 | CHRNB4 (0.54) | KDM4EFPR2EPHX2DRD2HTR2A | |
| SCHEMBL30566050 | 0.80 | KDM4E (0.38) | KDM4EKDM5ADRD2HTR2ADRD3 | |
| SCHEMBL18949684 | 0.78 | KDM4E (0.44) | KDM4EFPR2ALDH1A1EPHX2SSTR4 | |
| SCHEMBL10970722 | 0.78 | ATM (0.55) | KDM4EALDH1A1EPHX2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230338337-A1 | BIOMARKERS FOR CANCER THERAPY USING MDM2 ANTAGONISTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-10-26 | — | — | US | disclosed |
| US-20230313313-A1 | BIOMARKERS FOR CANCER THERAPY USING MDM2 ANTAGONISTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-10-05 | — | — | US | disclosed |
| EP-3322706-B1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2020-11-11 | — | — | EP | disclosed |
| US-20190127375-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2019-05-02 | — | — | US | disclosed |
| WO-2018136661-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS | ANDREWS STEVEN W (US) | 2018-07-26 | — | — | WO | disclosed |
| US-20170096425-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2017-04-06 | — | — | US | disclosed |
| WO-2017011776-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2017-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127375-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | KDM4E 695/4885FPR2 2607/4885KDM5A 1361/4885 |
| US-20230313313-A1 | BIOMARKERS FOR CANCER THERAPY USING MDM2 ANTAGONISTS | SKP2, MDM2, TP53 | KDM4E 1048/4885FPR2 3715/4885KDM5A 1165/4885 |
| US-20170096425-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | KDM4E 695/4885FPR2 2607/4885KDM5A 1361/4885 |
| US-20230338337-A1 | BIOMARKERS FOR CANCER THERAPY USING MDM2 ANTAGONISTS | IRF2BP2, BST2, IRF3 | KDM4E 4411/4885FPR2 1902/4885KDM5A 4036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.